Harrow (HROW) Total Non-Current Liabilities (2014 - 2024)
Harrow's (HROW) quarterly Total Non-Current Liabilities came in at $291.2 million in Q3 2024, up 40.04% year-on-year from $208.0 million in Q4 2023, and up 18.5% quarter-over-quarter from $245.7 million in Q2 2024.
Harrow (HROW) Total Non-Current Liabilities (2014 - 2024) Analysis & Trends
Harrow's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $291.2 million for Q3 2024.
- On a quarterly basis, Total Non-Current Liabilities rose 40.04% year-over-year to $291.2 million in Q3 2024; TTM through Sep 2024 was $291.2 million, a 40.04% increase from a year earlier, with the FY2023 full-year figure at $239.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities advanced to $291.2 million in Q3 2024 per HROW's latest filing, from $245.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $291.2 million in Q3 2024 and bottomed at $27.6 million in Q1 2021.
- The 4-year median for Total Non-Current Liabilities is $196.7 million (2023), against an average of $147.1 million.
- Across the five-year window, Total Non-Current Liabilities decreased 11.21% in 2021 and surged 40.04% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $29.8 million in 2020, then decreased by 7.59% to $27.6 million in 2021, then jumped by 766.65% to $239.0 million in 2023, then rose by 21.82% to $291.2 million in 2024.
- Per Business Quant, the three latest HROW Total Non-Current Liabilities figures stand at $291.2 million (Q3 2024), $245.7 million (Q2 2024), and $232.6 million (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 291.21 Mn |
| Jun 30, 2024 | 245.74 Mn |
| Mar 31, 2024 | 232.62 Mn |
| Dec 31, 2023 | 239.04 Mn |
| Sep 30, 2023 | 207.95 Mn |
| Jun 30, 2023 | 199.66 Mn |
| Mar 31, 2023 | 193.70 Mn |
| Mar 31, 2021 | 27.58 Mn |
| Dec 31, 2020 | 29.85 Mn |
| Sep 30, 2020 | 33.74 Mn |
| Jun 30, 2020 | 33.26 Mn |
| Mar 31, 2020 | 31.07 Mn |
| Dec 31, 2019 | 30.87 Mn |
| Sep 30, 2019 | 30.17 Mn |
| Jun 30, 2019 | 29.36 Mn |
| Mar 31, 2019 | 28.68 Mn |
| Dec 31, 2018 | 23.90 Mn |
| Sep 30, 2018 | 23.04 Mn |
| Jun 30, 2018 | 21.80 Mn |
| Mar 31, 2018 | 20.32 Mn |